API Gallery
The Remimazolam market is projected to register a CAGR of 8.2% from 2025 to 2035, propelled by growing demand for short-acting anesthetics that provide rapid onset and predictable recovery.
The Repaglinide market is anticipated to witness a steady CAGR of 5.3% from 2025 to 2035 due to the rising prevalence of type 2 diabetes and the increasing demand for fast-acting oral antidiabetic drugs.
The Repotrectinib market is expected to grow at a CAGR of 7.2% between 2025 and 2035, driven by the increasing number of patients diagnosed with ROS1-positive non-small cell lung cancer (NSCLC).
Sunitinib malate market is experiencing a CAGR of 6.9% during the forecast period, driven by the rising incidence of renal cell carcinoma, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
Sunitinib API market is experiencing a CAGR of 6.9% during the forecast period. The market growth is driven by rising global cancer incidence, expanding indications for Sunitinib in oncology, and increased generic drug manufacturing following the expiration of key patents.
Suplatast tosilate market is experiencing a CAGR of 8.8% during the forecast period, driven by rising demand for effective, non-steroidal treatments for allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis.
Survodutide market is experiencing a CAGR of 28% during the forecast period, driven by rising obesity and type 2 diabetes prevalence, expanding research in GLP-1/glucagon dual agonists, and increasing global investment in metabolic disorder therapeutics.
Suvorexant market is experiencing a CAGR of 6.4% during the forecast period, The market growth is primarily driven by the rising incidence of sleep disorders such as insomnia, particularly among the elderly population and working professionals experiencing high stress.
Tacrine market is experiencing a CAGR of 4.5% during the forecast period. Tacrine, an active pharmaceutical ingredient (API) used in the treatment of Alzheimer’s disease, has seen fluctuations in demand due to the development of newer, more effective drugs.
Tacrolimus monohydrate market is experiencing a CAGR of 6.5% during the forecast period. The market growth is driven by the increasing prevalence of organ transplantation and autoimmune diseases, which drive demand for Tacrolimus as an immunosuppressant drug.
Tacrolimus market is experiencing a CAGR of 6.5% during the forecast period. The market is driven by the increasing demand for Tacrolimus in immunosuppressive treatments, especially for organ transplant patients.
Tadalafil market is experiencing a CAGR of 6.5% during the forecast period, driven by the increasing demand for Tadalafil-based treatments for erectile dysfunction (ED) and pulmonary arterial hypertension (PAH).
Tafamidis Meglumine market is experiencing a CAGR of 7.2% during the forecast period. The market growth is driven fueled by the increasing prevalence of transthyretin amyloidosis (ATTR) and the approval of Vyndaqel and Vyndamax in multiple global markets.
Tafamidis API market is experiencing a CAGR of 8.8% during the forecast period. The market growth is driven by its increasing use in the treatment of transthyretin amyloidosis (ATTR), a rare, progressive disease.
Tafenoquine succinate API market is experiencing a CAGR of 8.8% during the forecast period. The market growth is driven by increasing demand for antimalarial drugs, particularly for Plasmodium vivax malaria.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
